FINWIRES · TerminalLIVE
FINWIRES

Neurizon Therapeutics Gets Ethics Committee Nod for Neurodegenerative Disease Phase 1 Study; Shares Gain 3%

By

Neurizon Therapeutics (ASX:NUZ) said the Bellberry Human Research Ethics Committee approved its phase 1 study to develop the NUZ-001 oral liquid formulation as a potential treatment for amyotrophic lateral sclerosis (ALS), according to a Wednesday filing with the Australian bourse.

ALS is a neurodegenerative disorder associated with progressive impairment in speech and swallowing function.

The phase 1 trial will enroll 32 healthy volunteers in Australia with the aim of generating safety and other data to guide formulation development and the broader program for NUZ-001, the company said.

The study is scheduled to start in the third quarter and be completed in the fourth quarter.

Neurizon Therapeutics shares gained 3% in recent Wednesday trade.

Related Articles

Asia

Miyoshi Signs Letter of Intent to Sell Stake in Core Power (Fujian); Shares Jump 13%

Miyoshi's (SGX:M03) shares surged nearly 13% on Wednesday after the manufacturer of precision pressed parts signed a non-binding letter of intent with Core Power (Fujian) Technology to dispose of its 42.11% stake in Core Power (Fujian).Under the letter, the company will dispose of the shares for an indicative consideration of 6 million yuan, according to a Tuesday filing with the Singapore Exchange.The completion of the disposal is subject to the execution of a definitive term sheet and shareholders' approval.

$SGX:M03
Asia

MTT Group to Raise HK$69 Million via Rights Offering

MTT Group (HKG:2350) said it was seeking to raise HK$68.8 million via a rights offering, according to a Tuesday filing with the Hong Kong bourse.The information technology company's shares fell over 10% in late morning trade Wednesday.The firm plans to offer eligible investors 2 rights shares for every five stocks held in the company. The rights shares will be priced at HK$0.275 each and investors will be offered allotments from a total pool of 250 million shares.Unsold shares will be offered to new investors.The firm will use proceeds from the offering to expand its business.

$HKG:2350
Asia

Guangzhou Development Issues 1 Billion Yuan in Super Short-Term Commercial Paper

Guangzhou Development (SHA:600098) issued super short-term commercial paper worth 1 billion yuan, according to a Shanghai bourse filing on Wednesday.The bonds have a coupon rate of 1.36% and a term of 270 days, maturing Jan. 31, 2027.The Chinese power company's shares rose 2% during the morning trade.

$SHA:600098